Novo Nordisk Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Lars Jorgensen

Chief Executive Officer (CEO)

kr.60.1m

Compensación total

Porcentaje del salario del CEO	28.5%
Permanencia del CEO	6.9yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lars Jorgensen en comparación con los beneficios de Novo Nordisk?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	kr.75b
Jun 30 2023	n/a	n/a	kr.67b
Mar 31 2023	n/a	n/a	kr.61b
Dec 31 2022	kr.60m	kr.17m	kr.56b
Sep 30 2022	n/a	n/a	kr.53b
Jun 30 2022	n/a	n/a	kr.51b
Mar 31 2022	n/a	n/a	kr.49b
Dec 31 2021	kr.58m	kr.17m	kr.48b
Sep 30 2021	n/a	n/a	kr.46b
Jun 30 2021	n/a	n/a	kr.44b
Mar 31 2021	n/a	n/a	kr.43b
Dec 31 2020	kr.57m	kr.14m	kr.42b
Sep 30 2020	n/a	n/a	kr.42b
Jun 30 2020	n/a	n/a	kr.41b
Mar 31 2020	n/a	n/a	kr.40b
Dec 31 2019	kr.55m	kr.14m	kr.39b
Sep 30 2019	n/a	n/a	kr.39b
Jun 30 2019	n/a	n/a	kr.38b
Mar 31 2019	n/a	n/a	kr.38b
Dec 31 2018	kr.41m	kr.11m	kr.39b
Sep 30 2018	n/a	n/a	kr.38b
Jun 30 2018	n/a	n/a	kr.39b
Mar 31 2018	n/a	n/a	kr.39b
Dec 31 2017	kr.32m	kr.9m	kr.38b

Compensación vs. Mercado: La compensación total de Lars($USD8.70M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD5.86M).

Compensación vs. Ingresos: La compensación de Lars ha sido consistente con los resultados de la empresa en el último año.

CEO

Lars Jorgensen (57 yo)

6.9yrs

Permanencia

kr.60,100,000

Compensación

Mr. Lars Fruergaard Jorgensen has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member of Management Board. Mr. Jorgensen served as Deputy Chair of the...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lars Jorgensen	President	6.9yrs	kr.60.10m	sin datos
Karsten Knudsen	Executive VP	5.8yrs	kr.21.50m	sin datos
Henrik Wulff	Executive VP of Product Supply	no data	kr.22.00m	0.0014% DKK 5.4m
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	kr.21.30m	0.000070% DKK 271.8k
Martin Lange	Executive VP of Development & Member of the Management Board	2.9yrs	kr.20.90m	sin datos
Marcus Schindler	EVP of Research & Early Development	2.8yrs	kr.20.90m	sin datos
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	sin datos	sin datos
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	sin datos	sin datos
Ludovic Helfgott	Executive VP	no data	sin datos	sin datos
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	less than a year	sin datos	sin datos
David Moore	Executive VP of Corporate Development & Member of Management Board	less than a year	sin datos	sin datos
Daniel Bohsen	CVP & Head of Investor Relations	no data	sin datos	sin datos

2.8yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NOVOB se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sylvie Gregoire	Independent Director	8.8yrs	kr.1.80m	sin datos
Helge Lund	Independent Chairman of the Board	6.8yrs	kr.3.10m	sin datos
Henrik Poulsen	Vice Chairman of the Board	2.8yrs	kr.2.00m	sin datos
Laurence Debroux	Independent Director	4.8yrs	kr.2.00m	sin datos
Martin MacKay	Independent Director	5.8yrs	kr.1.70m	sin datos
Andreas Fibig	Independent Director	5.8yrs	kr.1.40m	sin datos
Kasim Kutay	Non-Independent Director	6.8yrs	kr.1.20m	sin datos
Christina Law	Independent Director	1.8yrs	kr.1.30m	sin datos
Liselotte Hyveled	Employee Representative Director	1.8yrs	kr.800.00k	sin datos
Mette Jensen	Employee Non-Independent Representative Director	5.8yrs	kr.1.20m	sin datos
Thomas Rantzau	Employee Representative Non-Independent Director	5.9yrs	kr.1.00m	sin datos
Elisabeth Christensen	Employee Representative Director	1.8yrs	kr.800.00k	sin datos

5.8yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NOVOB se considera experimentada (5.8 años de antigüedad promedio).

Novo Nordisk Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Recent updates

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

New minor risk - Shareholder dilution

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Now 21% undervalued

Second quarter 2023 earnings released: EPS: kr.8.65 (vs kr.5.87 in 2Q 2022)

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Now 20% undervalued after recent price drop

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

First quarter 2023 earnings released: EPS: kr.8.81 (vs kr.6.24 in 1Q 2022)

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Full year 2022 earnings released

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 28,000 million worth of its shares.

Novo Nordisk Announces FDA Approval of Label Update for Rybelsus® (Semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes

Now 20% undervalued

Third quarter 2022 earnings released

Novo Nordisk A/S to Report First Half, 2023 Results on Aug 10, 2023

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad